Prospective validation for the usefulness of Genome-wide association study (GWAS) in predicting the effects of anti-viral therapy on chronic hepatitis C

Not Applicable

Recruiting

• Conditions: Chronic hepatitis C

• Registration Number: JPRN-UMIN000002580
• Lead Sponsor: Research Center for Hepatitis & Immunology, Kohnodai Hospital, International Medical Center of Japan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-10-08
• Study Completion: 2012-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients taking Sho-sai-koto(herbal medicine) 2) Autoimmune hepatitis 3) Patients with history of interstitial pneumonia 4) Patients with previous history of drug allergy against ribavirin, peginterferon alpha2a (Pegasys), peginterferon alpha2b (Pegintron), or other interferons 5) Patients with previous history of drug allergy against biological products such as vaccines 6) Liver cirrhosis, liver failure or hepatocellular carcinoma 7) Patients with the following laboratory data at the start of peginterferon and ribavirin combination therapy: WBC counts less than 4,000/microliter and Neutrophil counts less than 1,500/microliter; Platelets counts less than 90,000/microliter (peginterferon alpha2a) or 100,000/microliter(peginterferon alpha2b); Hemoglobin levelsless than 12g/dL 8) Women who are pregnant or have its possibility 9) Patients who refuse birth control, including male patients whose patners may have the chance to be pregnant 10) Patients whom the physicians in charge judge their enrollment inappropriate

Study & Design

• Study Type: Interventional
• Study Design: Not specified